Today: 9 June 2026
Browse Category

NASDAQ:AKRO 9 October 2025 - 14 December 2025

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk shares rebounded this week, rising about 7% in both Copenhagen and U.S. trading after EU regulators backed a higher-dose Wegovy, Ozempic launched in India at a lower price, and the company closed its Akero Therapeutics acquisition. The week began with a sharp selloff on competition fears and a Wall Street downgrade before sentiment reversed midweek.
14 December 2025
····
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk will pay up to $2.1 billion to license Omeros’s experimental MASP-3 inhibitor zaltenibart for rare blood and kidney disorders. Omeros receives $340 million upfront, with additional milestone and royalty payments possible. Omeros shares jumped about 65% on the news, while Novo’s stock fell 1.5%. The deal is expected to close by Q4 2025.
15 October 2025
···
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero shares jumped nearly 19% to $55 on October 9, 2025 after Novo Nordisk announced a $5.2 billion buyout at $54 per share plus a $6 contingent payment. Novo will pay $4.7 billion upfront and another $500 million if Akero’s lead drug, efruxifermin, wins FDA approval by 2031. The deal has board approval and is expected to close by late 2025, pending regulatory and shareholder clearance.
9 October 2025
···
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··

Stock Market Today

  • Euronext Updates AEX and AMX Indices: Adds Aalberts and CSG
    June 9, 2026, 1:23 PM EDT. Euronext, the Pan-European stock exchange, announced changes to the Netherlands' AEX and AMX indices, effective June 22. The AEX index, representing the top Dutch stocks, will include Aalberts, reflecting its market capitalization and liquidity. Meanwhile, the AMX, which tracks mid-cap Dutch companies, will add CSG. These periodic reviews ensure indices accurately represent the evolving Dutch market landscape, impacting fund trackers and investor portfolios tied to these benchmarks.

Latest articles

Archer Aviation Drops After Cathie Wood Selloff; What Traders Are Tracking

Archer Aviation Drops After Cathie Wood Selloff; What Traders Are Tracking

9 June 2026
Archer Aviation plunged 9.1% to $5.21 after ARK Invest dumped over 2.2 million shares worth $12.7 million, intensifying pressure as investors fled speculative growth stocks; with FAA certification still pending and heavy cash burn, Archer’s stock remains vulnerable to further selloffs if milestones slip.
Aurora Shares Fall as Uber Pulls Back, Tech Stocks Struggle

Aurora Shares Fall as Uber Pulls Back, Tech Stocks Struggle

9 June 2026
Aurora shares dropped 3.5% to $6.04 as tech and autonomous-driving stocks slid, with Uber’s recent block sale of 67.5 million shares at $7.10 still weighing on sentiment; Aurora reported a Q1 net loss of $223 million on $1 million revenue, expects continued losses, and may need to raise more capital to support its commercial ramp.
United Natural Foods Shares Fall After Revenue Miss

United Natural Foods Shares Fall After Revenue Miss

9 June 2026
United Natural Foods plunged 12.4% to $45.25 after quarterly revenue missed estimates, falling 4.2% to $7.72 billion versus the $7.80 billion consensus, with full-year guidance also slightly below Wall Street expectations, despite matching adjusted EPS and improved profit and debt metrics.
BlackBerry Shares Stall After QNX Push

BlackBerry Shares Slip Ahead of Results — What’s Moving BB Today

9 June 2026
BlackBerry’s U.S. shares plunged 8.5% to $8.50 as investors braced for the June 25 earnings report, with focus on whether the company can meet its bullish Q1 revenue forecast of $132–$140 million, well above analysts’ estimates, after QNX’s 20% revenue jump and $950 million royalty backlog last quarter.
Chip Selloff Trips Up Wall Street’s AI Rally

Chip Selloff Trips Up Wall Street’s AI Rally

9 June 2026
Nasdaq and S&P 500 tumbled midday, erasing early chip-stock gains as tech shares slid; Philadelphia Semiconductor Index dropped 2% after jumping 3%, with Broadcom, Micron, and Nvidia under pressure. Investors await key inflation data Wednesday and SpaceX’s massive IPO, both seen as catalysts for further volatility amid concerns that high valuations in AI and tech could face profit-taking if rate fears persist.
Go toTop